Thinking
laterally
about CAR-T

Our mission is to develop CAR-T therapies to improve treatment outcomes and save the lives of patients with refractory cancers.

imagecells.jpg

Caroline Hull, Allogeneic Team Lead, to present data on Leucid's allogeneic CAR T-cell platform at the 3rd Gamma Delta T Therapies Summit

26th-28th July 2022

Boston, MA

5d166a945fd97_edited.jpg

Our Science

CAR T-cell therapy is a revolutionary technology in which immune cells, called T-cells, are reprogrammed so they can recognise and destroy cancer cells.

Lateral CAR T-Cell Platform

Founded to translate 20 years of pioneering CAR-T research led by Dr John Maher at King's College London (King's), Leucid Bio has developed a proprietary portfolio based upon Dr Maher’s novel approach, in which the CAR structure has been redesigned to recapitulate the lateral distribution of signalling domains as observed in natural immune receptors. The technology gives properties to the CAR-Ts that enable them to consistently outperform previous generations of CAR-T therapies in pre-clinical studies; enhancing T-cell potency and generating a persistent long-term response with reduced toxicity.

pCAR + description (1).png
shutterstock_1275172360.jpg
T4 Immunotherapy

Leucid Bio’s T4 Immunotherapy is a pan-ErbB targeted autologous CAR T-cell product for patients with otherwise untreatable head and neck cancer. It is currently in Phase I, with 18 patients treated to date, of whom 10 have achieved disease stabilisation.

Novel Manufacturing Platforms

Leucid Bio has developed an improved, more rapid and scalable manufacturing process that relies on a simple blood draw.

1 (17).2.jpg
5d166a945fd97_edited.jpg

Our Science

CAR T-cell therapy is a revolutionary technology in which immune cells, called T-cells, are reprogrammed so they can recognise and destroy cancer cells.

Lateral CAR T-Cell Platform

Founded to translate 20 years of pioneering CAR-T research led by Dr John Maher at King's College London (King's), Leucid Bio has developed a proprietary portfolio based upon Dr Maher’s novel approach, in which the CAR structure has been redesigned to recapitulate the lateral distribution of signalling domains as observed in natural immune receptors. The technology gives properties to the CAR-Ts that enable them to consistently outperform previous generations of CAR-T therapies in pre-clinical studies; enhancing T-cell potency and generating a persistent long-term response with reduced toxicity.

CAR T cell.png
5d26f8578751d.png
T2, allogeneic gd T-cell platform

Leucid has developed a patented technique for generating gd T-cells from the peripheral blood of healthy donors, we call T2. T2 cells are a distinct population of gd T-cells and ideally suited for off-the-shelf cellular therapy.

T4 Immunotherapy

Leucid Bio’s T4 Immunotherapy is a pan-ErbB targeted autologous CAR T-cell product for patients with otherwise untreatable head and neck cancer. It is currently in Phase I, with 18 patients treated to date, of whom 10 have achieved disease stabilisation.

shutterstock_1275172360.jpg
Novel Manufacturing Platforms

Leucid Bio has developed an improved, more rapid and scalable manufacturing process that relies on a simple blood draw.

1 (17).2.jpg